期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 17, 期 2, 页码 560-565出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2020.1772632
关键词
Anthrax; protective antigen; vaccine; adjuvant; spherical particles; stability
资金
- Russian Science Foundation [18-14-00044]
- Russian Science Foundation [18-14-00044] Funding Source: Russian Science Foundation
The potential of stabilizing rPA for anthrax vaccine was demonstrated through the simultaneous application of tobacco mosaic virus spherical particles (SPs) and site-specific mutagenesis. The results support the development of a recombinant vaccine with modified rPA and SPs.
Anthrax is a zoonotic disease caused by the gram-positive spore-forming bacteriaBacillus anthracis. There is a need for safe, highly effective, long-term storage vaccine formulations for mass vaccination. However, the development of new subunit vaccines based on recombinant protective antigen (rPA) faces the problem of vaccine antigen instability. Here, the potential of simultaneous application of two different approaches to stabilize rPA was demonstrated. Firstly, we employed spherical particles (SPs) obtained from the tobacco mosaic virus (TMV). Previously, we had reported that SPs can serve as an adjuvant and platform for antigen presentation. In the current work, SPs were shown to increase the stability of the full-size rPA without loss of its antigenic properties. The second direction was site-specific mutagenesis of asparagine residues to avoid deamidation that causes partial protein degradation. The modified recombinant protein comprising the PA immunogenic domains 3 and 4 (rPA3 + 4) was stable during storage at 4 and 25 degrees C. rPA3 + 4 interacts with antibodies to rPA83 both individually and as a part of a complex with SPs. The results obtained can underpin the development of a recombinant vaccine with a full-size modified rPA (with similar amino acid substitutions that stabilize the protein) and SPs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据